Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs V.BTI


Primary Symbol: V.BTI.H Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by chrispion Apr 07, 2021 6:09am
188 Views
Post# 32947474

RE:Some calls about some things...

RE:Some calls about some things...
The thing that caused me the most grief from shareholders yesterday and today is that the corporate presentation (CP) still has the Q1 CY2021 data delivery predictions on it. Sorry folks. I cannot explain that one. Not even going to try. The company needs to edit page 4 of that document. Make another prediction or remove the prediction. 
 
I can explain it JD and thought I did with my post from a few days ago, that is:
 
This news has nothing to do with the study data readouts that are to be completed by the end of Q1/2021 and subsequently press released in the following weeks. I personally do not want to see three study readouts in one press release nor three separate press releases all announced on the same day as that is simply too much news for all interested parties to digest at once and makes no sense to do it that way. Let’s release them individually and allow them to be distributed and understood by the market. I’m certain shareholders and (potential) partners will be impressed! From my understanding, the studies we are awaiting data readouts for are in the 007, 004 and Progranulin programs.

<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse